Tharimmune, inc. announces pricing of $10 million public offering

Bridgewater, nj / accesswire / november 27, 2023 / tharimmune, inc. (nasdaq:thar) ("tharimmune" or the "company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic conditions, today announced the pricing of an underwritten public offering of 10,000,000 shares of common stock (or pre-funded warrants ("pre-funded warrants") in lieu thereof). each share of common stock (or pre-funded warrant) is being sold at a public offering price of $1.00 per share (inclusive of the pre-funded warrant exercise price) for gross proceeds of $10,000,000, before deducting underwriting discounts and offering expenses.
THAR Ratings Summary
THAR Quant Ranking